AVTX — Avalo Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Annual cashflow statement for Avalo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-63.5	-84.4	-41.7	-31.5	-35.1
Depreciation
Deferred Taxes
Non-Cash Items	25.4	8.97	9.94	9.93	-9.5
Discontinued Operations
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-4.44	2.84	4.77	-9.24	-4.71
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Cash from Operating Activities	-40.5	-70.9	-26.8	-30.7	-49.1
Capital Expenditures	-0.063	-0.113	-0.095	-0.158	0
Purchase of Fixed Assets
Other Investing Cash Flow Items	11.2	0	—	0.025	0.356
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Other Investing Cash Flow
Cash from Investing Activities	11.1	-0.113	-0.095	-0.133	0.356
Financing Cash Flow Items	3.79	0	—	—	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	44.8	107	-14.7	25	176
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	15.4	35.8	-41.5	-5.77	127